Neuropeptide Y and Sympathovagal Balance

• Status: Completed
• Trial end date: 2019-04-15
• Target enrollment: 0
• Participant gender: Male

Summary

Neuropeptide Y (NPY) activates the sympathetic and vagal nervous systems through the Y1 and Y2 receptors. This double-blind placebo-controlled crossover study investigated the sympathovagal balance during three exercises on a cycloergometer in healthy volunteers treated with saxagliptin (DPP4 inhibitor).

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Eric Grouzmann
• Collaborators: grégoire millet; grégoire wuerzner; Nicolas Bourdillon; Philippe Eugster
• Treatments: Saxagliptin

Criteria

Inclusion Criteria:

1. Healthy male subjects aged between 18 and 30 years.

2. Non smoking

3. Practicing at least 3 hours physical activity per week

4. Absence of significant findings in the medical history and physical examination as judged by the Investigator, especially for cardiovascular, pulmonary, haematological and nervous systems

5. Ability to understand the procedures, agreement to participate and willingness to give written informed consent

6. Co-operative attitude and availability for scheduled visits over the entire study period.

Exclusion Criteria:

1. Use of any medication the week prior to study. Paracetamol is permissible before and during study as a concomitant medication but only with Investigator's permission.

2. History of major cardiovascular, pulmonary, hepatic, immunological, renal, haematological, gastrointestinal, genitourinary, neurological, or rheumatologic disorders

3. rhinosinusitis

4. Urinary tract infection

5. Hypertension defined as supine blood pressure >150/90 mmHg or recurrent hypotensive events considered as clinically relevant or documented orthostatic hypotension